The WARRIOR trial in contrast intensive medical remedy with normal care in a cohort of girls with suspected ischemia with nonobstructive coronary illness.
Learn Healio’s in-depth protection of the WARRIOR trial, together with skilled perspective.
Researchers enrolled 2,476 ladies with suspected ischemia with nonobstructive coronary illness (INOCA), outlined by coronary angiography or coronary CTA, and randomly assigned them to intensive medical therapyor normal care follow-up each 6 months.
WARRIOR s the biggest research of girls with INOCA and the one trial with a serious hostile CV consequence on this inhabitants.
At 5 years, the intensive technique didn’t scale back threat for the first composite consequence CV dying, nonfatal MI, stroke, hospitalization for angina or hospitalization for HF.
The researchers s the COVID-19 pandemic, mixed with the constraints of a realistic research design, had a big affect on the outcomes and the information shouldn’t be interpreted as endorsing discontinuation of statins, ACE inhibitors or s for ladies with INOCA.
The WARRIOR trial was introduced on the 2025 American School of Cardiology Scientific Session.
